Retirement Systems of Alabama Boosts Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Retirement Systems of Alabama raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 390,082 shares of the biopharmaceutical company’s stock after purchasing an additional 814 shares during the period. Retirement Systems of Alabama’s holdings in Halozyme Therapeutics were worth $18,650,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HALO. Congress Asset Management Co. grew its position in shares of Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after buying an additional 1,988,238 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Halozyme Therapeutics by 698.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock valued at $13,756,000 after purchasing an additional 251,711 shares during the last quarter. Boston Trust Walden Corp boosted its position in shares of Halozyme Therapeutics by 54.0% in the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock valued at $39,073,000 after purchasing an additional 239,321 shares during the period. South Street Advisors LLC purchased a new position in Halozyme Therapeutics during the 3rd quarter worth approximately $9,812,000. Finally, Hantz Financial Services Inc. purchased a new stake in Halozyme Therapeutics in the third quarter valued at approximately $9,260,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 0.5 %

HALO stock opened at $57.94 on Friday. The company’s 50-day moving average price is $51.18 and its 200 day moving average price is $54.38. Halozyme Therapeutics, Inc. has a 52 week low of $34.36 and a 52 week high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The company has a market cap of $7.37 billion, a P/E ratio of 19.19, a P/E/G ratio of 0.43 and a beta of 1.25.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on HALO shares. JMP Securities lifted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a report on Tuesday. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Finally, Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.